InvestorsHub Logo
Followers 50
Posts 9479
Boards Moderated 2
Alias Born 10/25/2007

Re: rosemountbomber post# 186

Thursday, 03/13/2025 12:01:25 PM

Thursday, March 13, 2025 12:01:25 PM

Post# of 188
2024 ASCO Annual Meeting: it's written on the wall

Median overall survival of 20.6 months was observed following two administrations of CAN-2409 + valacyclovir in NSCLC patients with progressive disease despite immune checkpoint inhibitor therapy compared to published results of median overall survival of 11.6 months observed with standard of care docetaxel-based chemotherapy in a similar patient population

CAN-2409 treatment resulted in activation of the systemic immune response after two administrations of CAN-2409, including increased numbers of circulating cytotoxic and memory T cells associated with subsequent prolonged survival, and a beneficial effect on both injected and uninjected tumors
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CADL News